Abstract
In the last ten years the prevention of respiratory distress syndrome (RDS) has been performed using drugs able to enhance fetal lung maturity and particularly surfactant synthesis by type II pneumocytes. Among the substances that have been employed, Ambroxol, given in high doses, allowed positive results to be obtained in both animals [1,2] and humans [3–7]. In humans Ambroxol, a hydroxylated derivative of Bromhexine, originally used as a mucolytic drug, has showed the ability to modify type II pneumocyte ultrastructure [8,9] and to increase the alveolar surfactant secretion.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Van Petten, G. R., Mears, G. J. and Taylor, P. The effect of NA 872 on pulmonary maturation in the fetal lamb and rabbit. Am J Obstet Gynecol 1978; 130: 35.
Egberts, J., Fontijne, P. and Wamsteker, K. Indication of increase of lecithin/sphingomyelin (L/S) ratio in lung fluid of lambs maternally treated with metabolite VIII of Bisolvon. Biol Neonate 1976; 29: 315.
Lowenberg, E., Jimenez, L., Martinez, M. and Pommier, M. Effects of Ambroxol (NA 872) on biochemical fetal lung maturity and prevention of the respiratory distress syndrome. In: Progress in Respiration Research, Basel: Karger, 1981; 240.
Muller-Tyl, E. and Salzer, H. Einflub von Dexamethason und Ambroxol auf die Reifung der fetalen Lunge. Atemwegs- Lungenerkrankungen 1978; 4 (1): 42.
Di Renzo, G. C., Anceschi, M. M. and Cosmi, E. V. Lung surfactant enhancement in utero. Eur J Obstet Gynecol Reprod Biol 1989; 32: 1.
Lowenberg, E., Escobedo, F. and Jimenez, L. Prevention of the respiratory distress syndrome with Ambroxol. In: Cosmi, E. V. and Scarpelli, E. M. eds. Pulmonary Surfactant System, Amsterdam. Elsevier, 1983; 205.
Wauer, R. R. Medical treatment of neonatal hyaline membrane disease using Bromhexine, Ambroxol and CDP-choline. In Cosmi, E. V. and Scarpelli, E. M. eds. Pulmonary Surfactant System, Amsterdam. Elsevier, 1983; 173.
Elmer, G. and Kapanci, Y. Morphological approach to surfactant secretion in the lungs with particular reference to Ambroxol. Prog Resp Res 1981; 15: 234.
Kapanci, Y. and Elmer, G. Ambroxol and surfactant secretion. Experimental studies on the incorporation of 3H-palmitate into pulmonary surfactant. In: Cosmi, E. V. and Scarpelli, E. M. eds. Pulmonary Surfactant System, Amsterdam: Elsevier, 1983.
Patrick, J., Campbell, K., Carmichael, L., Natale, R. and Richardson, B. Pattern of human fetal breathing movements during the last 10 weeks of pregnancy. Obstet Gynecol 1980; 56: 24.
Luerti, M., Casolati, E., Rossi, G., Zavattini, G. and Corbella, E. Alternatives to steroids for prevention of respiratory distress syndrome (RDS). In: Vignali, M., Cosmi, E. V. and Luerti, M. eds. Diagnosis and Treatment of Fetal Lung Immaturity, Milan: Masson, 1985; 116.
Schwenzel, W. and Jung, H. Pranatale behandlungsmethoden zur vermeidung eines atemnotsyndroms bei frungeborenen kindern. Gynakologie 1975; 8 198.
Wauer, R. R., Schmalisch, G., Menzel, K. et al. The antenatal use of Ambroxol (Bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study. Biol Res Preg 1982; 3 (2): 84.
Editor information
Editors and Affiliations
Copyright information
© 1991 Macmillan Publishers Limited
About this chapter
Cite this chapter
Revelli, A., Oliveri, M.G., Molina, G., Parolini, P., Mascher, M., Massobrio, M. (1991). Induction of fetal pulmonary maturity with Ambroxol: side effects and therapeutic effectiveness. In: Cosmi, E.V., Di Renzo, G.C., Anceschi, M.M. (eds) The Surfactant System of the Lung. Palgrave, London. https://doi.org/10.1007/978-1-349-12553-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-349-12553-1_12
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-12555-5
Online ISBN: 978-1-349-12553-1
eBook Packages: EngineeringEngineering (R0)